Zobrazeno 31 - 40
of 150
pro vyhledávání: ''
Autor:
M. Sambasiva Rao, Seth B. Krantz, David J. Bentrem, Hidayatullah G. Munshi, Morgan R. Barron, Paul J. Grippo, Rosa F. Hwang, Surabhi Dangi-Garimella, Mario A. Shields, Eric C. Cheon
Publikováno v:
Molecular Cancer Research. 9:1294-1304
Pancreatic cancer is associated with a pronounced fibrotic reaction that was recently shown to limit delivery of chemotherapy. To identify potential therapeutic targets to overcome this fibrosis, we examined the interplay between fibrosis and the key
Autor:
Kieron Dunleavy, Wyndham H. Wilson, Delong Liu, Yihong Ye, Adrian Wiestner, Edgar G. Rizzatti, Nalini Raghavachari, Therese White, Megan M. Tweito, Qiuyan Wang, Peter J. Munson, Marc A. Weniger, Patricia Pérez-Galán
Publikováno v:
Clinical Cancer Research. 17:5101-5112
Purpose: Proteasome inhibition disrupts protein homeostasis and induces apoptosis. Up to 50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used gene expression profiling to investigate the connection between proteasom
Autor:
Jutta Blank, David A. Ruddy, Elisa Degenkolbe, Dorothea Haasen, Pascal Furet, Joseph Schoepfer, Ralph Tiedt, Brent A. Appleton, Sabrina Wagner, Francesco Hofmann, Michael D. Jones, John Monahan, Markus Wartmann, Clive Mccarthy, Peter Drueckes, William R. Sellers, Emily Buck
Publikováno v:
Cancer Research. 71:5255-5264
The emergence of drug resistance is a primary concern in any cancer treatment, including with targeted kinase inhibitors as exemplified by the appearance of Bcr-Abl point mutations in chronic myeloid leukemia (CML) patients treated with imatinib. In
Autor:
Xiao Yi Yang, Takuya Osada, H. Kim Lyerly, Timothy M. Clay, Michael A. Morse, Bryan M. Clary, David S. Hsu, Ivan Spasojevic, Minyong Chen, Jeffrey VanDeusen, Wei Chen
Publikováno v:
Cancer Research
Wnt/β-catenin pathway activation caused by adenomatous polyposis coli (APC) mutations occurs in approximately 80% of sporadic colorectal cancers (CRC). The antihelminth compound niclosamide downregulates components of the Wnt pathway, specifically D
Autor:
Adi F. Gazdar, Hisao Imai, Junichi Soh, John D. Minna, Luc Girard, Jill E. Larsen, Mitsuo Sato, Yang Xie, Michael Peyton, Masatomo Mori, Noriko Yanagitani, Noriaki Sunaga, David S. Shames, Kyoichi Kaira
Publikováno v:
Molecular Cancer Therapeutics. 10:336-346
Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non–small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown
Autor:
George D. Demetri, Nathanael S. Gray, Marzia Capelletti, Michael J. Eck, Wei Zheng, Liping Wang, Pasi A. Jänne, James G. Christensen, Keith D. Wilner, Katsuhiro Okuda, Takaaki Sasaki, James E. Butrynski, Scott J. Rodig, Geoffrey I. Shapiro
Publikováno v:
Cancer Research. 70:10038-10043
The ALK kinase inhibitor crizotinib (PF-02341066) is clinically effective in patients with ALK-translocated cancers, but its efficacy will ultimately be limited by acquired drug resistance. Here we report the identification of a secondary mutation in
Autor:
Ana M. Plutín, Edson Luis Maistro, Amanda Blanque Becceneri, Alzir A. Batista, Cecília Patrícia Popolin, Márcia Regina Cominetti
Publikováno v:
Molecular Cancer Research. 16:A16-A16
Cancer remains a major public health problem, accounting for one in six deaths worldwide. One of the most common types of cancer in women is breast cancer, which is extremely heterogeneous and composed of different subtypes. The majority of drugs cur
Publikováno v:
Molecular Cancer Research. 16:B21-B21
Breast cancer is a heterogeneous disease, and stratification of patients is fundamental to the success of treatment modalities. Breast tumors deficient in BRCA1 are mostly associated with basal-like breast cancers, and targeted therapeutics for this
Publikováno v:
Molecular Cancer Research. 16:A30-A30
Luminal breast cancers account for ~75% of newly diagnosed cases and express estrogen receptor (ER) and a range of progesterone receptor (PR)-positive cells. Although adjuvant hormone therapies that target ER actions (e.g., tamoxifen or aromatase inh
Autor:
Cristina M. Karp, Eileen White, Kevin Bray, Robert S. DiPaola, Hsin-Yi Chen, Michael May, Shridar Ganesan, Vassiliki Karantza-Wadsworth
Publikováno v:
Molecular Cancer Research. 7:1487-1496
Apoptosis resistance is a hallmark of cancer linked to disease progression and treatment resistance, which has led to the development of anticancer therapeutics that restore apoptotic function. Antiapoptotic Bcl-2 is frequently overexpressed in refra